Modality
Degrader
MOA
FGFRi
Target
AuroraA
Pathway
Lipid Met
SLEHNSCC
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
Nov 2020
→ Mar 2031
Phase 1Current
NCT08340454
2,209 pts·HNSCC
2023-02→TBD·Active
NCT06614828
1,171 pts·HNSCC
2020-11→2031-03·Not yet recruiting
3,380 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-245.0y awayInterim· HNSCC
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Not yet…
P1
Active
Catalysts
Interim
2031-03-24 · 5.0y away
HNSCC
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08340454 | Phase 1 | HNSCC | Active | 2209 | OS |
| NCT06614828 | Phase 1 | HNSCC | Not yet recr... | 1171 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA |